# US 2016/0244408 A1 · Carbazole derivatives acting on 5-ht7 receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0244408 A1
- Document ID: US20160244408A1
- Status: Published application
- Kind: A1
- Application number: 14/629,821
- Filed: 2015-02-24
- Published: 2016-08-25
- Earliest claimed: 2015-02-24
- Assignees: Korea Institute of Science and Technology
- Applicants: Korea Institute of Science and Technology
- Inventors: Hyunah CHOO; Gyo Chang KEUM; Youngjae KIM; MI Young YEOM
- Web page: https://patentgrep.com/patent/US20160244408A1

## CPC

- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT7 receptor. The carbazole derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for the 5-HT7 serotonin receptor and antagonistic activities against the 5-HT7 serotonin receptor. Further disclosed are pharmaceutical compositions including the compounds as active ingredients. The pharmaceutical compositions are useful as therapeutic and prophylactic agents for central nervous system diseases where antagonistic activities against 5-HT7 are required, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.

## Claims

### Claim 1

A carbazole derivative represented by Formula 1:
wherein X is CH2 or C(O),
Y is selected from NR1R2, piperidinyl groups substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups,
n is an integer from 2 to 5,
R1 and R2 are identical or different and are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 are optionally bonded together to form a ring,
R3 and R4 are identical or different and are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The carbazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein the carbazole derivative represented by Formula 1 is selected from compounds represented by Formulae 2 to 5:
wherein X is CH2 or C(O),
n is an integer from 2 to 5, and
R1 and R2 are identical or different and are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 are optionally bonded together to form a ring;
wherein X, n, and R2 are as defined in Formula 2, and
R3 is selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl;
wherein X and n are as defined in Formula 2, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; and
wherein X and n are as defined in Formula 2.

### Claim 3 (depends on 1)

The carbazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein Y is selected from methylbutylaminyl, methylbenzylaminyl, pyrrolidinyl, azepanyl, morpholinyl, 4-methylpiperidinyl, 3-methylpiperidinyl, 3,5-dimethylpiperidinyl, 4-phenylpiperidinyl, 4-benzylpiperidinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl, 4-(2-methoxyphenyl)piperazinyl, 4-(2-hydroxyphenyl)piperazinyl, 4-benzylpiperazinyl, and 4-(benzoisoxazol-3-yl)piperazinyl.

### Claim 4 (depends on 1)

The carbazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein the carbazole derivative represented by Formula 1 is selected from:
6-(butyl(methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one;
6-(benzyl(methyl)amino)-1-(9H-carbazol-9-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(pyrrolidin-1-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-methylpiperidin-1-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(3-methylpiperidin-1-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(3,5-dimethylpiperidin-1-yl)hexan-1-one;
6-(azepan-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-morpholinohexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-phenylpiperidin-1-yl)hexan-1-one;
6-(4-benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
6-(4-acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-methylpiperazin-1-yl)hexan-1-one;
6-(4-benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
6-(4-benzo[d]isoxazol-3-yl)piperazin-1-yl)-1-(9H-carbazol-9-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-(2-hydroxyphenyl)piperazin-1-yl)hexan-1-one;
1-(9H-carbazol-9-yl)-6-(4-(2-methoxyphenyl)piperazin-1-yl)hexan-1-one;
5-(butyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one;
5-(benzyl(methyl)amino)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(pyrrolidin-1-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-methylpiperidin-1-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(3-methylpiperidin-1-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(3,5-dimethylpiperidin-1-yl)pentan-1-one;
5-(azepan-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-morpholinopentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-phenylpiperidin-1-yl)pentan-1-one;
5-(4-benzylpiperidin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one;
5-(4-acetylpiperazin-1-yl)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-methylpiperazin-1-yl)pentan-1-one;
5-(4-benzylpiperazinyl)-1-(9H-carbazol-9-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-(2-hydroxyphenyl)piperazin-1-yl)pentan-1-one;
1-(9H-carbazol-9-yl)-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentan-1-one;
4-(4-benzylpiperazin-1-yl)-1-(9H-carbazol-9-yl)butan-1-one;
1-(9H-carbazol-9-yl)-4-(4-(2-hydroxyphenyl)piperazin-1-yl)butan-1-one;
1-(9H-carbazol-9-yl)-4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-one;
N-butyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine;
N-benzyl-6-(9H-carbazol-9-yl)-N-methylhexane-1-amine;
9-(6-(pyrrolidin-1-yl)hexyl)-9H-carbazole;
9-(6-(4-methylpiperidin-1-yl)hexyl)-9H-carbazole;
9-(6-(3-methylpiperidin-1-yl)hexyl)-9H-carbazole;
9-(6-(3,5-dimethylpiperidin-1-yl)hexyl)-9H-carbazole;
9-(6-(azepan-1-yl)hexyl)-9H-carbazole;
4-(6-(9H-carbazol-9-yl)hexyl)morpholine;
9-(6-(4-phenylpiperidin-1-yl)hexyl)-9H-carbazole;
9-(6-(4-benzylpiperidin-1-yl)hexyl)-9H-carbazole;
1-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)ethanone;
9-(6-(4-methylpiperazin-1-yl)hexyl)-9H-carbazole;
9-(6-(4-benzylpiperazin-1-yl)hexyl)-9H-carbazole;
2-(4-(6-(9H-carbazol-9-yl)hexyl)piperazin-1-yl)phenol;
9-(6-(4-(2-methoxyphenyl)piperazin-1-yl)hexyl)-9H-carbazole;
9-(5-(4-phenylpiperidin-1-yl)pentyl)-9H-carbazole;
9-(5-(4-benzylpiperazin-1-yl)pentyl)-9H-carbazole;
2-(4-(5-(9H-carbazol-9-yl)pentyl)piperazin-1-yl)phenol;
9-(5-(4-(2-methoxyphenyl)piperazin-1-yl)pentyl)-9H-carbazole;
9-(4-(4-phenylpiperidin-1-yl)butyl)-9H-carbazole;
2-(4-(4-(9H-carbazol-9-yl)butyl)piperazin-1-yl)phenol;
9-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-9H-carbazole;
9-(3-(4-phenylpiperidin-1-yl)propyl)-9H-carbazole;
9-(3-(4-benzylpiperazin-1-yl)propyl)-9H-carbazole;
2-(4-(3-(9H-carbazol-9-yl)propyl)piperazin-1-yl)phenol; and
9-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)-9H-carbazole.

### Claim 5

A method for preparing a carbazole derivative represented by Formula 1:
wherein X is CH2 or C(O),
Y is selected from NR1R2, piperidinyl groups substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups,
n is an integer from 2 to 5,
R1 and R2 are identical or different and are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 are optionally bonded together to form a ring,
R3 and R4 are identical or different and are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl,
the method comprising reacting a compound represented by Formula 6:
wherein X and n are as defined in Formula 1, with a compound represented by Formula 7:
Y—H (7)
wherein Y is as defined in Formula 1, in an organic solvent.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the organic solvent is selected from the group consisting of acetonitrile, dichloromethane, dichloroethane, tetrahydrofuran, lower alcohol, N,N-dimethylformamide, dimethyl sulfoxide, ethyl acetate, dioxane, chloroform, benzene, and toluene.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the reaction is carried out under reflux at 25 to 200° C. for 3 to 24 hours.

### Claim 8 (depends on 7)

The method according to claim 7, wherein Y is selected from methylbutylaminyl, methylbenzylaminyl, pyrrolidinyl, azepanyl, morpholinyl, 4-methylpiperidinyl, 3-methylpiperidinyl, 3,5-dimethylpiperidinyl, 4-phenylpiperidinyl, 4-benzylpiperidinyl, 4-methylpiperazinyl, 4-acetylpiperazinyl, 4-(2-methoxyphenyl)piperazinyl, 4-(2-hydroxyphenyl)piperazinyl, 4-benzylpiperazinyl, and 4-(benzoisoxazol-3-yl)piperazinyl.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the compound of Formula 6 is prepared by reacting carbazole with a compound of Formula 8:
wherein X is CH2 or C(O), and
n is an integer from 2 to 5, in an organic solvent.

### Claim 10

A pharmaceutical composition for preventing and treating a central nervous system disease, comprising a carbazole derivative represented by Formula 1:
wherein X is CH2 or C(O),
Y is selected from NR1R2, piperidinyl groups substituted with R3 and R4, piperazinyl groups in which the nitrogen atom is substituted with R5, and morpholinyl groups,
n is an integer from 2 to 5,
R1 and R2 are identical or different and are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 are optionally bonded together to form a ring,
R3 and R4 are identical or different and are each independently selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl, or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the central nervous system disease is selected from the group consisting of depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, smooth muscle-related diseases, and combinations thereof.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the carbazole derivative represented by Formula 1 is selected from compounds represented by Formulae 2 to 5:
wherein X is CH2 or C(O),
n is an integer from 2 to 5, and
R1 and R2 are identical or different and are each independently selected from C1-C6 alkyl, phenyl, and benzyl, with the proviso that R1 and R2 are optionally bonded together to form a ring;
wherein X, n, and R2 are as defined in Formula 2, and
R3 is selected from hydrogen, C1-C6 alkyl, phenyl, and benzyl;
wherein X and n are as defined in Formula 2, and
R5 is selected from C1-C6 alkyl, C1-C4 alkylcarbonyl, phenyl substituted with C1-C4 alkyloxy, hydroxyphenyl, benzyl, and benzoisoxazol-3-yl; and
wherein X and n are as defined in Formula 2.
